Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
MA Cenci, K Skovgård, P Odin - Neuropharmacology, 2022 - Elsevier
Dopamine replacement therapy with l-DOPA is the most efficacious symptomatic treatment
for Parkinson's disease, but its utility is limited by a development of motor fluctuations and …
for Parkinson's disease, but its utility is limited by a development of motor fluctuations and …
Continuous dopaminergic stimulation as a treatment for Parkinson's disease: current status and future opportunities
Levodopa‐induced motor complications remain an important source of disability for many
patients with Parkinson's disease. Substantial laboratory evidence indicates that motor …
patients with Parkinson's disease. Substantial laboratory evidence indicates that motor …
Maladaptive striatal plasticity in L-DOPA-induced dyskinesia
Dopamine (DA) replacement therapy with l-DOPA remains the most effective treatment for
Parkinson's disease, but causes dyskinesia (abnormal involuntary movements) in the vast …
Parkinson's disease, but causes dyskinesia (abnormal involuntary movements) in the vast …
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
V Sgambato-Faure, MA Cenci - Progress in neurobiology, 2012 - Elsevier
Dyskinesias represent a major complication of dopamine replacement therapy in
Parkinson's disease (PD) and have prompted a search for alternative treatments. The most …
Parkinson's disease (PD) and have prompted a search for alternative treatments. The most …
L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission
Dyskinesia is a serious motor complication caused by prolonged administration of l-DOPA to
patients affected by Parkinson's disease. Accumulating evidence indicates that l-DOPA …
patients affected by Parkinson's disease. Accumulating evidence indicates that l-DOPA …
AMPA receptors as therapeutic targets for neurological disorders
Almost every neurological disease directly or indirectly affects synapse function in the brain.
However, these diseases alter synapses through different mechanisms, ultimately resulting …
However, these diseases alter synapses through different mechanisms, ultimately resulting …
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys
D Rylander, H Iderberg, Q Li, A Dekundy, J Zhang… - Neurobiology of …, 2010 - Elsevier
L-DOPA remains the gold-standard treatment for Parkinson's disease but causes motor
fluctuations and dyskinesia. Metabotropic glutamate receptor type 5 (mGluR5) has been …
fluctuations and dyskinesia. Metabotropic glutamate receptor type 5 (mGluR5) has been …
Dyskinesia in Parkinson's disease: mechanisms and current non‐pharmacological interventions
Dopamine replacement therapy in Parkinson's disease is associated with several unwanted
effects, of which dyskinesia is the most disabling. The development of new therapeutic …
effects, of which dyskinesia is the most disabling. The development of new therapeutic …
Targeting β-arrestin2 in the treatment of l-DOPA–induced dyskinesia in Parkinson's disease
Parkinson's disease (PD) is characterized by severe locomotor deficits and is commonly
treated with the dopamine (DA) precursor l-3, 4-dihydroxyphenylalanine (l-DOPA), but its …
treated with the dopamine (DA) precursor l-3, 4-dihydroxyphenylalanine (l-DOPA), but its …